

FHP Strategies Trump Health Care and Administrative Executive Order (EO) Tracker

EO Number	Date	Title	Issue Area	Summary	Link
14148	1/20/2025	Initial Rescissions of Harmful Executive Orders and Actions	Administrative	This EO revokes 78 executive actions from the previous administration, including those related to diversity, equity and inclusion (DEI), climate policy, COVID-19 response, immigration; and labor.	https://www.whitehouse.gov/presidential- actions/2025/01/initial-rescissions-of-harmful- executive-orders-and-actions/
Memorandum	1/20/2025	Regulatory Freeze Pending Review	Administrative	This memorandum pauses the issuance, publication and enforcement of new federal rules pending review by department or agency heads appointed by the incoming administration. The memorandum instructs agencies to withdraw unpublished rules from the <i>Federal Register</i> and delay the effective dates of recently published or issued rules for 60 days to evaluate their legal, factual and policy implications.	https://www.whitehouse.gov/presidential- actions/2025/01/regulatory-freeze-pending- review/
14155	1/20/2025	Withdrawing the United States from the World Health Organization	Health Care	This EO declares that the United States intends to withdraw from the World Health Organization (WHO). The EO directs the secretary of State and the director of the Office of Management and Budget to pause the future transfer of any U.S. government funds, support or resources to the WHO, recall and reassign U.S. government personnel or contractors working with the WHO.	https://www.whitehouse.gov/presidential- actions/2025/01/withdrawing-the-united-states- from-the-worldhealth-organization/
14158	1/20/2025	Establishing and Implementing the President's "Department of Government Efficiency"	Administrative	This EO establishes the Department of Government Efficiency to implement the President's DOGE Agenda by modernizing Federal technology and software in an attempt to maximize governmental efficiency and productivity.	https://www.whitehouse.gov/presidential- actions/2025/01/establishing-and-implementing- the-presidents-department-of-government- efficiency/
14168	1/20/2025	Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government	Health Care/Social Issues	This EO declares that it is the policy of the United States to recognize two sexes, male and female. The EO directs the Executive Branch to enforce all sex-protective laws to promote this the defenitions as laid out in the EO.	https://www.whitehouse.gov/presidential- actions/2025/01/defending-women-from-gender- ideology-extremism-and-restoring-biological-truth to-the-federal-government/
14151	1/20/2025	Ending Radical and Wasteful Government DEI Programs and Preferencing	Social Issues	This EO declares that it the policy of the United States to terminate all federal programs, policies and mandates related to diversity, equity and inclusion (DEI), diversity, equity, inclusion and accessibility (DEIA) and environmental justice. The EO directs the Office of Management and Budget (OMB), the Office of Personnel Management (OPM) and the attorney general to oversee the review, revision and eliminationprograms including DEI offices, positions like chief diversity officers, equity action plans and related grants or contracts.	https://www.whitehouse.gov/presidential- actions/2025/01/ending-radical-and-wasteful- government-dei-programs-and-preferencing/
14173	1/21/2025	Ending Illegal Discrimination and Restoring Merit-Based Opportunity	Administrative/Social Issues	This EO eliminates DEI initiatives across the federal government and prohibits related practices that prioritize race, sex or other characteristics over individual merit, competence and civil-rights law compliance.	https://www.whitehouse.gov/presidential- actions/2025/01/ending-illegal-discrimination-and restoring-merit-based-opportunity/
14177	1/23/2025	President's Council of Advisors on Science and Technology (PCAST)	Science and Technology	This EO establishes the President's Council of Advisors on Science and Technology (PCAST). The EO reduces the PCAST to 24 members and narrows the council's focus.	https://www.whitehouse.gov/presidential- actions/2025/01/presidents-council-of-advisors- on-science-and-technology/
14179	1/23/2025	Removing Barriers to American Leadership in Artificial Intelligence	Artificial Intelligence	This EO states that an interagency group must develop the Trump Administration's new policy on AI within six months. The interagency group includes the assistant to the president for science and technology (APST), the special advisor for AI and crypto and the assistant to the president for national security affairs (APNSA).	https://www.whitehouse.gov/presidential- actions/2025/01/removing-barriers-to-american- leadership-in-artificial-intelligence/
14182	1/24/2025	Enforcing the Hyde Amendment	Health Care	This EO reaffirms the Hyde Amendment's prohibition on using federal taxpayer dollars to fund or promote elective abortions. The EO also revokes two Biden-era EOs, Securing Access to Reproductive and Other Health Care Services (EO 14079) and the <i>Protecting Access to Reproductive Healthcare Services</i> (EO 14076.	https://www.whitehouse.gov/presidential- actions/2025/01/enforcing-the-hyde-amendment,
Memorandum	1/24/2025	Memorandum for the Secretary of State, the Secretary of Defense, the Secretary of Health and Human Services, the Administrator of the United States Agency for International Development	International Relations/Health Care	This memorandum revokes the Presidential Memorandum of Jan. 28, 2021 to reinstate the Mexico City Policy, which requires the secretary of state, the secretary of defense, the secretary of health and human services and the administrator of the United States Agency for International Development to agree as a condition of their receipt of federal funds to neither perform nor promote abortion as a method of family planning in other nations.	https://www.whitehouse.gov/presidential- actions/2025/01/memorandum-for-the-secretary- of-state-the-secretary-of-defense-the-secretary-of- health-and-human-services-the-administrator-of- the-united-states-for-international-development/
14184	1/27/2025	Reinstating Service Members Discharged Under the Military's COVID- 19 Vaccination Mandate	National Security/Health Care	This EO directs the secretary of defense and secretary of homeland security to make reinstatement available to all members of the military who were discharged for refusing the COVID-19 vaccine.	https://www.whitehouse.gov/presidential- actions/2025/01/reinstating-service-members- discharged-under-the-militarys-covid-19- vaccination-mandate/
14187	1/28/2025	Protecting Children from Chemical and Surgical Mutilation	Health Care/Social Issues	This EO directs agencies to withdraw funding for medical interventions that alter a child's biological sex, including puberty blockers, hormone treatments and surgeries.	https://www.whitehouse.gov/presidential- actions/2025/01/protecting-children-from- chemical-and-surgical-mutilation/

14192	1/31/2025	Unleashing Prosperity Through Deregul	Administrative	This EO establishes a regulatory reduction policy, requiring agencies to eliminate at least ten existing regulations for every new one introduced. It mandates that the total incremental cost of regulations for fiscal year (FY) 2025 be significantly reduced to less than zero. OMB will oversee compliance.	https://www.whitehouse.gov/fact-sheets/2025/01/fact-sheet-president-donald-i-trump-launches-massive-10-to-1-deregulation-initiative/
14195	2/1/2025	Imposing Duties to Address the Synthetic Opioid Supply Chain in the People's Republic of China	Trade/Opioids	This EO imposes a 10% tariff on all Chinese goods. The EO discusses the sustained importation of synthetic opioids as a threat to the United States.	https://www.whitehouse.gov/presidential- actions/2025/02/imposing-duties-to-address-the- synthetic-opioid-supply-chain-in-the-peoples- republic-of-china/
14201	2/5/2025	Keeping Men Out of Women's Sports	Social Issues	This EO establishes a federal policy that states that only biological females can compete in female athletic categories.	https://www.whitehouse.gov/presidential- actions/2025/02/keeping-men-out-of-womens- sports/
Memorandum	2/7/2025	Memorandum for the Heads of Executive Departments and Agencies	Administrative	This Memorandum directs the heads of executive departments and agencies to review all funding that agencies provide to NGOs. The EO states that the heads of agencies shall align future funding decisions with the interests of the United States and with the goals and priorities of my Administration, as expressed in executive actions; as otherwise determined in the judgment of the heads of agencies; and on the basis of applicable authorizing statutes, regulations, and terms.	https://www.whitehouse.gov/presidential- actions/2025/02/memorandum-for-the-heads-of- executive-departments-and-agencies/
14210	2/11/2025	Implementing the President's "Department of Government Efficiency" Workforce Optimization Initiative	Administrative/DOGE	This EO initiates a major restructuring of the federal workforce by imposing a 4-to-1 hiring to termination ratio, requiring agencies to hire only one employee for every four departures, with exceptions for public safety, law enforcement and immigration enforcement. Department of Government Efficiency (DOGE) will play a role in overseeing hiring and implementation of this EO.	https://www.whitehouse.gov/presidential- actions/2025/02/implementing-the-presidents- department-of-government-efficiency-workforce- optimization-initiative/
14212	2/13/2025	Establishing the President's Make America Healthy Again Commission	Health Care/MAHA	This EO states that the United States will combat rising rates of mental health disorders, obesity, diabetes and other chronic diseases. It directs all federally funded health research to empower Americans through transparency and open-source data and avoid or eliminate conflicts of interest. It also directs the National Institutes of Health (NIH) and other health-related research funded by the federal government to prioritize "gold-standard" research on the root causes of why "Americans get sick."	https://www.whitehouse.gov/presidential- actions/2025/02/establishing-the-presidents- make-america-healthy-again-commission/
14214	2/14/2025	Keeping Education Accessible and Ending Covid-19 Vaccine Mandates in Schools	Vaccines	This executive order requires the secretaries of education and HHS to provide a plan to the president to end COVID-19 school mandates. The Secretary of Education must also issue guidance to affected entities about their legal obligations regarding parental authority, religious freedom, disability accommodations and equal protection, as it relates to COVID-19 school mandates.	https://www.whitehouse.gov/presidential- actions/2025/02/keeping-education-accessible- and-ending-covid-19-vaccine-mandates-in- schools/
14216	2/18/2025	Expanding Access to In Vitro Fertilization	Health Care	This EO directs the assistant to the president for domestic policy to submit to the president a list of policy recommendations on protecting access to in-vitro fertilization (IVF) and aggressively reducing out-of-pocket and health plan costs for IVF treatment within 90 days.	https://www.whitehouse.gov/presidential- actions/2025/02/expanding-access-to-in-vitro- fertilization/
14215	2/18/2025	Ensuring Accountability for All Agencies	Administrative	This EO increases presidential oversight and control over independent regulatory agencies, "ensuring that all executive branch officials remain accountable to the President." This EO also mandates that all significant regulatory actions from executive departments and independent agencies be submitted for review by the Office of Information and Regulatory Affairs (OIRA) before publication. This EO also directs the Office of Management and Budget (OMB) to establish performance standards for independent agency heads, review agency spending to align with presidential priorities, and require agency heads to coordinate with the White House Domestic Policy and National Economic Councils.	https://www.whitehouse.gov/presidential- actions/2025/02/ensuring-accountability-for-all- agencies/
14219	2/19/2025	Ensuring Lawful Governance and Implementing the President's "Department of Government Efficiency" Regulatory Initiative	Adminstrative/DOGE	This EO directs federal agencies to review and rescind regulations that exceed statutory authority, impose excessive costs or hinder economic and technological progress. It states that agency heads, in coordination with their DOGE Team Leads and and OMB, must compile lists of such regulations within 60 days and develop a plan for their removal.	https://www.whitehouse.gov/presidential- actions/2025/02/ensuring-lawful-governance-and- implementing-the-presidents-department-of- government-efficiency-regulatory-initiative/
14217	2/19/2025	Commencing the Reduction of the Federal Bureaucracy	Administrative	This EO mandates a significant reduction in the federal bureaucracy by eliminating non-essential government entities as deemed by the President. This EO states that agency heads must submit reports justifying their existence. OMB is directed to reject funding requests inconsistent with the order's objectives. This EO also instructs senior White House advisors to identify further government entities and advisory committees for termination.	https://www.whitehouse.gov/presidential- actions/2025/02/commencing-the-reduction-of- the-federal-bureaucracy/
14221	2/25/2025	Making America Healthy Again by Empowering Patients with Clear, Accurate, and Actionable Healthcare Pricing Information	Health Care	This EO aims to increase clear, accurate, and actionable healthcare pricing information. The EO directs the Departments of the Treasury, Labor, and Health and Human Services (HHS) to rapidly implement and enforce the Trump healthcare price transparency regulations introduced in President Trump's first term. The EO orders the departments to ensure that hospitals and insurers disclose prices and take action to make prices comparable across hospitals and insurers. Departments will also update their enforcement policies	https://www.whitehouse.gov/presidential- actions/2025/02/making-america-healthy-again- by-empowering-patients-with-clear-accurate-and- actionable-healthcare-pricing-information/

14222	2/26/2025	Implementing the President's "Department of Government Efficiency" Cost Efficiency Initiative	Administrative/DOGE	This EO initiates oversight of federal spending on contracts, grants and loans toincrease transparency in government spending. This EO directs agencies, in coordination with their Department of Government Efficiency (DOGE) team leads, to build a centralized technological system within the agency to record every payment issued by the agency pursuant to each of the agency's covered contracts and grants, along with a brief, written justification for each payment submitted by the agency employee who approved the payment. The EO also orders each agency head to review all existing covered contracts and grants and, where appropriate and consistent with applicable law, terminate or modify (including through renegotiation) such covered contracts and grants to reduce overall Federal spending or reallocate spending to promote efficiency and advance the policies of my Administration.	https://www.whitehouse.gov/presidential- actions/2025/02/implementing-the-presidents- department-of-government-efficiency-cost- efficiency-initiative/
14226	3/2/2025	Amendment to Duties to Address the Flow of Illicit Drugs across our Northern Border	Trade/Opioids	This EO amends the EO entitled <i>Imposing Duties to Address the Flow of Illicit Drugs Across Our Northern Border.</i> The initial EO's implementation was paused until March 4. The amendment will allow eligible Canadian goods to enter the United States under the <i>de minimis</i> provision. The <i>de minimis</i> provision allows duty-free imports of cargo valued at \$800 or less per recipient per day.	https://www.whitehouse.gov/presidential- actions/2025/03/amendment-to-duties-to- address-the-flow-of-illicit-drugs-across-our- northern-border/
14227	3/2/2025	Amendment to Duties to Address the Situation at our Southern Border	Trade/Opioids	This EO amends the EO entitled <i>Imposing Duties to Address the Flow of Illicit Drugs Across Our Southern Border</i> . The initial EO's implementation was paused until March 4. The amendment will allow eligible Mexican goods to enter the United States under the <i>de minimis</i> provision. The de minimis provision allows duty-free imports of cargo valued at \$800 or less per recipient per day.	https://www.whitehouse.gov/presidential- actions/2025/03/amendment-to-duties-to- address-the-situation-at-our-southern-border/
14228	3/3/2025	Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China	Trade/Opioids	This EO amends the EO entitled <i>Imposing Duties to Address the Synthetic Opioid Supply Chain in the People's Republic of China</i> . The initial EO imposed a 10% tariff on all Chinese goods. The amendment changes the tariff rate from 10% to 20% (20% tariff will be applied in addition to any existing tariffs).	https://www.google.com/url?q=https://www.whitehouse.gov/presidential-actions/2025/03/furtheramendment-to-duties-addressing-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china/&sa=D&source=editors&ust=174129579022 4539&usg=AOvVaw3j76VNvZC7Zr0j_Bnc2uuO
14227	3/6/2025	Amendment to Duties to Address the Situation at our Southern Border	Trade/Opioids	This EO aims to minimize disruption to the United States automotive industry and automotive workers by adjusting the tariffs imposed on articles of Mexico in Executive Order 14194 of February 1, 2025 (Imposing Duties to Address the Situation at Our Southern Border). The EO states that the additional rate of duty on potash that is not subject to subsection (a) of this section shall be reduced to 10% in lieu of 25%.	https://www.whitehouse.gov/presidential- actions/2025/03/amendment-to-duties-to- address-the-flow-of-illicit-drugs-across-our- southern-border/
14231	3/6/2025	Amendment to Duties to Address the Flow of Illicit Drugs across our Northern Border	Trade/Opioids	This EO aims to minimize disruption to the United States automotive industry and automotive workers by adjusting the tariffs imposed on articles of Canada in Executive Order 14193 of February 1, 2025 (Imposing Duties to Address the Flow of Illicit Drugs Across Our Northern Border). The EO states that the additional rate of duty on potash that is not subject to subsection (a) of this section shall be reduced to 10% in lieu of 25%.	https://www.whitehouse.gov/presidential- actions/2025/03/amendment-to-duties-to- address-the-flow-of-illicit-drugs-across-our- northern-border-0c3c/
Memorandum	3/11/2025	Ensuring the Enforcement of Federal Rule of Civil Procedure 65(c)	Legal Proceedings	This memorandum states that it is the policy of the United States to demand that parties seeking injunctions against the Federal Government must cover the costs and damages incurred if the Government is ultimately found to have been wrongfully enjoined or restrained. It also directs the heads of executive departments and agencies (agencies), in consultation with the Attorney General, to ensure that their respective agencies properly request under Rule 65(c) that Federal district courts require plaintiffs to post security equal to the Federal Government's potential costs and damages from a wrongly issued injunction.	https://www.whitehouse.gov/presidential- actions/2025/03/ensuring-the-enforcement-of- federal-rule-of-civil-procedure-65c/
14238	3/14/2025	Continuing the Reduction of the Federal Bureaucracy	Administrative	This EO eliminates the non-statutory components and functions of various governmental entities. The EO states that various government entities shall be eliminated to the maximum extent consistent with applicable law, and such entities shall reduce the performance of their statutory functions and associated personnel to the minimum presence and function required by law. The EO directs the head of each governmental entity listed, within 7 days of the date of this order, to submit a report to the Director of the Office of Management and Budget confirming full compliance with this order and explaining which components or functions of the governmental entity, if any, are statutorily required and to what extent. Targeted entities include the Federal Mediation and Conciliation Service; the United States Agency for Global Media; the Woodrow Wilson International Center for Scholars in the Smithsonian Institution; the Institute of Museum and Library Services; the United States Interagency Council on Homelessness; the Community Development Financial Institutions Fund; and the Minority Business Development Agency.	https://www.whitehouse.gov/presidential- actions/2025/03/continuing-the-reduction-of-the- federal-bureaucracy/
14240	3/20/2025	Eliminating Waste and Saving Taxpayer Dollars by Consolidating Procurement	Administrative	This EO directs agency heads, within 60 days of the date of this order, to consult with the agency's senior procurement officials, submit to the Administrator proposals, and to have the General Services Administration conduct domestic procurement with respect to common goods and services for the agency, where permitted by law. This EO states that within 90 days of the date of this order, the Administrator shall submit a comprehensive plan to the Director of OMB for the General Services Administration to procure common goods and services across the domestic components of the Government, where permitted by law. Additionally, this EO directs the Director of OMB to designate the Administrator as the executive agent for all Government-wide acquisition contracts for information technology within 30 days.	https://www.whitehouse.gov/presidential- actions/2025/03/eliminating-waste-and-saving- taxpayer-dollars-by-consolidating-procurement/

14243	3/20/2025	Stoping Waste, Fraud and Abuse by Eliminating Information Silos	Administrative	This EO directs agency heads to take all necessary steps, to the maximum extent consistent with law, to ensure Federal officials designated by the President or Agency Heads (or their designees) have full and prompt access to all unclassified agency records, data, software systems, and information technology systems — or their equivalents if providing access to an equivalent dataset does not delay access — for purposes of pursuing Administration priorities related to the identification and elimination of waste, fraud, and abuse. This includes authorizing and facilitating both the intra- and inter-agency sharing and consolidation of unclassified agency records. This EO also orders agency heads, within 30 days of the date of this order, to rescind or modify all agency guidance that serves as a barrier to the inter- or intra-agency sharing of unclassified information specified in the EO.	https://www.whitehouse.gov/presidential-actions/2025/03/stopping-waste-fraud-and-abuse-by-eliminating-information-silos/
14255	3/31/2025	Establishing the United States Investment Accelerator	Adminstrative/Economic	This EO establishes, within the Department of Commerce, an office named the United States Investment Accelerator (Investment Accelerator). The Investment Accelerator will facilitate and accelerate investments above \$1 billion in the United States by assisting investors as they navigate United States Government regulatory processes efficiently, reduce regulatory burdens where consistent with applicable law, increase access to and use of our national resources where appropriate and consistent with applicable law, facilitate research collaborations with our national labs, and work with State governments in all 50 States to reduce regulatory barriers to, and increase, domestic and foreign investment in the United States. The Investment Accelerator will be headed by an Executive Director and staffed with legal, transactional, operational, and support staff as directed by the Secretary of Commerce.	https://www.whitehouse.gov/presidential- actions/2025/03/establishing-the-united-states- investment-accelerator/
14257	4/2/2025	Regulating Imports with a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits	Trade/Economic	This EO instates a baseline 10% tariffs on all U.S. imports which will go into effect on April 5, 2025. The EO also includes higher tariffs for specific countries which can be found in Annex I of the EO and will go into effect on April 9. Some countries seeing higher tariff rates include China with a 34% tariff, the European Union with a 20% tariff, Vietnam with a 46% tariff, and Taiwan with a 32% tariff.	https://www.whitehouse.gov/presidential- actions/2025/04/regulating-imports-with-a- reciprocal-tariff-to-rectify-trade-practices-that- contribute-to-large-and-persistent-annual-united- states-goods-trade-deficits/
14256	4/2/2025	Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China as Applied to Low-Value Imports	Trade/Opioids	This EO buils on EO 14195 and states that duty-free de minimis treatment under 19 U.S.C. 1321(a)(2)(C) shall no longer be available for products of the PRC (which include products of Hong Kong) described in section 2(a) of Executive Order 14195, as amended by EO 14228, including international postal packages sent to the United States through the international postal network from the PRC or Hong Kong, that are entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 am eastern daylight time on May 2, 2025. The EO requires that the Secretary of Commerce, within 90 days of the date of this order, to submit a report to the President regarding the impact of this order on American industries, consumers, and supply chains and making recommendations for further action as he deems necessary.	https://www.whitehouse.gov/presidential- actions/2025/04/further-amendment-to-duties- addressing-the-synthetic-opioid-supply-chain-in- the-peoples-republic-of-china-as-applied-to-low- value-imports/
14259	4/8/2025	Amendment to Reciprocal Tariffs and Updated Duties as Applied to Low- Value Imports from the People's Republic of China	Trade/Economic	This EO responds to retaliatory tariffs from the PRC and places an 84% tariff on imports from the PRC. The amended duty rate will continue to apply on top of existing duties, including 20% fentanyl tariffs, effectively bringing the tariff rate on Chinese goods to 104%.	
14267	4/9/2025	Reducing Anti-Competitive Regulatory Behaviors	Regulatory/Administrative	This EO directs Agency heads, in consultation with the Chairman of the Federal Trade Commission and the Attorney General, to complete a review of all regulations subject to their rulemaking authority and identify those that: (i) create, or facilitate the creation of, de facto or de jure monopolies; (ii) create unnecessary barriers to entry for new market participants; (iii) limit competition between competing entities or have the effect of limiting competition between competing entities; (iv) create or facilitate licensure or accreditation requirements that unduly limit competition; (v) unnecessarily burden the agency's procurement processes, thereby limiting companies' ability to compete for procurements; or (vi) otherwise impose anti-competitive restraints or distortions on the operation of the free market. Within 70 days of this EO, each agency head shall provide to the Chairman and the Attorney General a list of regulations identified by the categories specified above.	https://www.whitehouse.gov/presidential- actions/2025/04/reducing-anti-competitive- regulatory-barriers/
14266	4/9/2025	Modifying Reciprocal Tariff Rates to Reflect Trading Partner Retaliation and Alignment	Trade/Economic	This EO suspends country-specific ad valorem rates of duty, as discussed in EO 14257, Regulating Imports with a Reciprocal Tariff to Rectify Trade Practices that Contribute to Large and Persistent Annual United States Goods Trade Deficits . These tariffs are suspended until 12:01 a.m. eastern daylight time on July 9, 2025.	https://www.whitehouse.gov/presidential- actions/2025/04/modifying-reciprocal-tariff-rates- to-reflect-trading-partner-retaliation-and- alignment/

	ı	T			
14273	4/15/2025	Lowering Drug Prices by Once Again Putting America First	Health Care/Drug Pricing	The EO includes the following provisions group by topic area: Medicare Drug Price Negotiation: The EO directs the HHS Secretary to seek comment on new negotiation guidance, and to make recommendations on how to stabilize and reduce Part D premiums. The EO also directs the HHS Secretary to work with Congress to eliminate the "pill penalty" by "aligning" the treatment of small molecule drugs with biological products. New Drug Pricing Model: The EO directs the HHS Secretary to take steps to develop and implement a "rulemaking plan" to test a new payment model to obtain "better value" for high-cost Medicare drugs. 340B: The EO directs the HHS Secretary to conduct a survey to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments (HOPDs), and to consider adjustments to align Medicare payment with the acquisition cost. These steps are likely a precursor to Medicare ASP-based payment cuts to 340B-acquired drugs administered in the HOPD. The EO also directs the HHS Secretary to reinstitute a program from President Trump's first term to make insulin and injectable epinephrine available at or below the 340B discounted price paid by Federal Qualified Health Centers. Site-Neutrality: The EO directs the HHS Secretary to consider regulations to ensure that Medicare payment is not encouraging a shift in drug administration volume away from physician office settings to HOPDs. Drug Manufacturer Anti-Competitive Behavior: The EO directs the HHS Secretary to conduct public listening sessions with the Departments of Justice and Commerce, and the Federal Trade Commission and issue a report to reduce anti-competitive behavior from pharmaceutical manufacturers. PBM Transparency: The EO directs the Secretary of Labor to propose regulations to improve employer health plan fiduciary transparency into the direct and indirect compensation received by PBMs. Other Provisions: The EO directs the FDA to issue a report providing recommendations to accelerate the approval of generics and biosi	https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/
14274	4/15/2025	Restoring Common Sense to Federal Procurement	Administrative	This EO states that it is the policy of the United States to create the most agile, effective, and efficient procurement system possible by removing undue barriers, such as unnecessary regulations, while simultaneously allowing for the expansion of the national and defense industrial bases is paramount. This EO directs the Administrator, in coordination with the other members of the Federal Acquisition Regulatory Council (FAR Council), within 180 days of the date of this order, to take appropriate actions to amend the FAR to ensure that it contains only provisions that are required by statute or that are otherwise necessary to support simplicity and usability, strengthen the efficacy of the procurement system, or protect economic or national security interests.	https://www.whitehouse.gov/presidential- actions/2025/04/restoring-common-sense-to- federal-procurement/
14271	4/16/2025	Ensuring Commercial, Cost-Effective Solutions in Federal Contracts	Administrative	This EO states that it is policy of the Trumo Administration that agencies shall procure commercially available products and services, including those that can be modified to fill agencies' needs, to the maximum extent practicable, including pursuant to the Federal Acquisition Streamlining Act of 1994. This EO directs agency's contracting officers, within 60 days of the date of this order, to review of all open agency solicitations, presolicitation notices, solicitation notices, award notices, and sole source notices for non-commercial products or services.	https://www.whitehouse.gov/presidential- actions/2025/04/ensuring-commercial-cost-effective- solutions-in-federal-contracts/
Memorandum	4/17/2025	Extension of Hiring Freeze	Administrative	This memorandum extends, through July 15, 2025, the freeze on the hiring of Federal civilian employees within the executive branch, as initially directed in the Presidential Memorandum of January 20, 2025	https://www.whitehouse.gov/presidential- actions/2025/04/extension-of-hiring-freeze/
14281	4/23/2025	Restoring Equality of Opportunity and Meritocracy	Administrative/Workforce	This EO eliminates the use of disparate-impact liability in all contexts to the maximum degree possible. This EO also revokes: (a) the Presidential approval of July 25, 1966, of the Department of Justice Title VI regulations (31 Fed. Reg. 10269), as applied to 28 C.F.R. 42.104(b)(2) in full; and (b) the Presidential approval of July 5, 1973, of the Department of Justice Title VI regulations (38 Fed. Reg. 17955, FR Doc. 73-13407), as applied to the words "or effect" in both places they appear in 28 C.F.R. 42.104(b)(3), and as applied to 28 C.F.R. 42.104(b)(6)(ii) and 28 C.F.R. 42.104(c)(2) in full.	https://www.whitehouse.gov/presidential- actions/2025/04/restoring-equality-of- opportunity-and-meritocracy/
14284	4/24/2025	Strengthening Probationary Periods in the Federal Service	Administrative/Workforce	This EO issues a new Civil Service Rule XI that will supersede subpart H. Under Civil Service Rule XI, agencies will have to affirmatively determine that the continued employment of individuals serving probationary or trial periods would benefit the Federal service before such appointments are finalized.	https://www.whitehouse.gov/presidential- actions/2025/04/strengthening-probationary- periods-in-the-federal-service/
14289	4/29/2025	Addressing Certain Tariffs on Imported Articles	Trade/Economic	The EO sets out the procedure for determining which of multiple tariffs shall apply to an article when that article is subject to more than one action.	https://www.whitehouse.gov/presidential- actions/2025/04/addressing-certain-tariffs-on- imported-articles/

14292	5/4/2025	Improving the Safety and Security of Biological Research	Health Care/Research	This EO ends federal funding for gain-of-function research in countries where the White House deems there is not adequate oversight to ensure that the countries are compliant with United States oversight standards and policies. The EO also pauses research using infectious pathogens and toxins in the U.S. and requires the Director of the Office of Science and Technology Policy (OSTP), within 120 days, to revise or replace the 2024 "United States Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential. This EO contains enforcement and reporting mechanisms in an attempt to strengthen oversight.	https://www.whitehouse.gov/presidential- actions/2025/05/improving-the-safety-and- security-of-biological-research/
14293	5/4/2025	Regulatory Relief to Promote Domestic Production of Critical Medicines	Health Care/Drugs	This EO directs FDA to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews, and working with domestic manufacturers to provide early support before facilities come online. The EO also directs the FDA to increase fees for and inspections of foreign manufacturing plants, and to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers. The EO also directs the Environmental Protection Agency (EPA) to accelerate the construction of pharmaceutical manufacturing facilities.	https://www.whitehouse.gov/presidential- actions/2025/05/regulatory-relief-to-promote- domestic-production-of-critical-medicines/
14297		Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to America	Drug Pricing	This EO directs the U.S. Trade Representative and Secretary of Commerce to take action to ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States. The EO also directs HHS to communicate MFN price targets to manufacturers by June 11, 2025 and establish a mechanism through which patients can buy drugs directly from manufacturers at the MFN price. If manufacturers do not make "significant progress" in voluntarily offering their drugs at the MFN price, the EO directs CMS to take certain aggressive actions - including proposing a "rulemaking plan to impose MFN pricing."	https://www.whitehouse.gov/presidential- actions/2025/05/delivering-most-favored-nation- prescription-drug-pricing-to-american-patients/
14298	5/12/2025	Modifying Reciprocal Tariff Rates to Reflect Discussion with the People's Republic of China	Tariffs	This EO modifes the HTSUS to suspend for a period of 90 days application of the additional ad valorem duties imposed on the PRC listed in Annex I to Executive Order 14257, as amended by Executive Order 14259 and Executive Order 14266, and clarified in the Presidential Memorandum of April 11, 2025 (Clarification of Exceptions Under Executive Order 14257 of April 2, 2025, as Amended), and to instead impose on articles of the PRC an additional ad valorem rate of duty as set forth herein, pursuant to the terms of, and except as otherwise provided in, Executive Order 14257, as modified by this order.	https://www.whitehouse.gov/presidential- actions/2025/05/modifying-reciprocal-tariff-rates- to-reflect-discussions-with-the-peoples-republic- of-china/
14303	5/23/2025	Restoring Gold Standard Science	Research/Science	This EO directs, within 30 days of the date of the order, the Director of the Office of Science and Technology Policy (OSTP Director) to, in consultation with the heads of relevant agencies, issue guidance for agencies on implementation of "Gold Standard Science" in the conduct and management of their respective scientific activities.	https://www.whitehouse.gov/presidential- actions/2025/05/restoring-gold-standard-science/